anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Endovascular treatment for patients with symptomatic nonacute middle cerebral artery occlusion remains clinically challenging, and proof of a beneficial effect on functional outcome is lacking. We aim to evaluate the effectiveness and safety of endovascular recanalization for patients with symptomatic nonacute middle cerebral artery occlusion.
METHODS: Ninety-eight patients with symptomatic atherosclerotic nonacute middle cerebral artery occlusion were divided into drug treatment groups (42) and endovascular treatment groups (56). The rate of recanalization, peri-procedural complications, and follow-up results were evaluated.
RESULTS: Among the 56 patients who received endovascular treatment, 53 (94.6%) achieved successful recanalization. The rate of peri-procedural complications was 7.1% (4/56), and the death rate was 1.8% (1/56). Any stroke within 90 days was 7.1% (4/56). Among the 42 patients in drug treatment group, any stroke within 90 days was 19.0% (8/42), death rate was 0.
CONCLUSION: Among patients with symptomatic nonacute middle cerebral artery occlusion with a short length of occlusion and a moderate-to-good collateral circulation, endovascular treatment seems to be safe. And endovascular treatment could reduce the recurrence rate of stroke.
Glucagon 1mg/ml solution for subcutaneous injection. Size and frequency of dosing will be determined by the AP algorithm. Duration: 3 days.
The present invention refers to a process for stabilizing LAA in an aqueous medium, which includes the step of contacting the LAA with at least one compound capable of forming hydrogen bridges with the LAA. In another aspect, the invention relates to a stable aqueous LAA composition which includes, in addition to said ascorbic acid, at least one compound which is linked to the LAA by hydrogen bridges, and to a process for preparing it. The present invention further relates to an emulsion including, in its aqueous phase, at least one compound linked to levogyre ascorbic acid (LAA) by hydrogen bridges. Further according to the present invention a vitamin product is provided, in which a stable LAA composition as described above is contained in organic envelopes which enable a gradual and prolonged release of the LAA into the organism. The vitamin product may further include a compound capable of stimulating the metabolism of the fibroblasts. The present invention further relates to a method for cosmetic, therapeutical or nutritional treatment, which includes the administration of a composition as described above.
This study will investigate the use of SMART (Sensory Motor Arousal Regulation Treatment) with adults experiencing symptoms related to PTSD (Post-Traumatic Stress Disorder). In addition to the more well-known symptoms of PTSD (e.g., intrusive memories, avoidance, hypervigilance, and emotion dysregulation), chronic traumatic stress seems to overwhelm the brain's capacity to make sense of sensory information, affecting how traumatized people experience their own bodies and their surroundings. SMART builds on the sensory integration theory of intentionally engaging the senses via movement, touch, body awareness, and balance. The SMART protocol has been used effectively to treat children who have experienced psychological trauma, and the investigators will be investigating its use with adults. Participants enrolled in the study will be randomly assigned to one of two treatment conditions - i) SMART, or ii) wait list (i.e., delayed treatment). Study participation will involve 8, 1-hour sessions of SMART, as well as pre-treatment, post-treatment, and 3-month follow-up assessments. For those assigned to the wait list condition, the same 8 SMART sessions will be offered after the 3-month follow-up assessment is complete, with no further assessment required.
Patients under mechanical ventilation who are suspected to be recovered and ready to return to spontaneous ventilation often undergo an spontaneous breathing trial (SBT) before extubation and liberation from mechanical ventilation. During the test, which lasts from 30 minutes to 2 hours , the patient receives minimal support from the ventilator, and the ICU team observes if the patient develops any signs or symptoms of discomfort or respiratory distress. If the patient tolerates the test, he or she is considered ready for extubation. The Neurally Adjusted Ventilatory Assist (NAVA) is a new mode of ventilation, shown to improve patient-ventilator synchrony. It has not been tested during SBTs. Our objective is to compare the performance of NAVA with the commonly used Pressure Support ventilation, during an SBT. Patients considered to be ready for an SBT by the ICU team will undergo two SBTs in random order: one in pressure support, and the other on NAVA, with a 1-hour interval between the tests. Ventilatory parameters and patient-ventilator interaction variables will be compared among the two tests.

This study will help us understand if NAVA can be used during an SBT, which might be important for patients who are being ventilated with NAVA before the SBT is suggested, especially those how present a high asynchrony rate when ventilated with Pressure Support Mode.
A pharmaceutical composition comprising 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline -2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof, a pressurised or liquefied gas propellant, and a flavouring agent and/or a sweetening agent is useful in the treatment of reversible obstructive airways disease.  The composition preferably contains nedocromil sodium as active ingredient.  Flavouring agents which may be used include menthol and peppermint oil.  Sweetening agents which may be used include sugar, aspartame, cyclamates and saccharin or salts thereof.  The composition preferably includes both a flavouring agent and a sweetening agent.  Any conventional aerosol propellant may be used, eg a mixture of Propellant 12 and Propellant 114, and the composition is preferably packaged in a conventional pressurised aerosol canister fitted with a dispensing metering valve.
Studies of the addition of a progestin product to an estrogen replacement regimen for seven or more days of a cycle of estrogen administration have reported a lowered incidence of endometrial hyperplasia. Morphological and biochemical studies of endometrial suggest that 10–13 days of a progestin are needed to provide maximal maturation of the endometrium and to eliminate any hyperplastic changes. Whether this will provide protection from endometrial carcinoma has not been clearly established.

There are possible risks which may be associated with the inclusion of progestin in estrogen replacement regimen, including adverse effects on carbohydrate and lipid metabolism. The dosage used may be important in minimizing these adverse effects.

A decrease in glucose tolerance has been observed in a small percentage of patients on estrogen-progestin combination treatment. The mechanism of this decrease is obscure. For this reason, diabetic patients should be carefully observed while receiving such therapy.
The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
PURPOSE: To attain easy emulsification by vibration or stirring and rapid separation at the time when the resultant emulsion is left stand by combining a surfactant with a specified phase substituting agent in a cosmetic or dermal compsn. consisting of an aq. phase and an oil phase. CONSTITUTION: This cosmetic or dermal compsn. consists of an aq. phase and an oil phase and contains >=0.25 wt.% surfactant in at least one of the phases to the whole weight of the compsn. and about 0.02-5 wt.% phase substituting agent in the aq. phase. The phase substituting agent is made of an alkyldimethylbenzylammonium chloride represented by the formula (where R is a 12-16C satd. straight chain alkyl) or a mixture of such compds., especially lauryldimethylbenzylammonium chloride or myristyldimethylbenzylammonium chloride. When the surfactant is contained in the aq. phase, it is preferably an anionic, nonionic or amphoteric surfactant. When the surfactant is contained in the oil phase, it is preferably a nonionic surfactant.
The present invention belongs to the field of biological techniques, particularly to a functional corn short peptide product with low molecular weight, a method for preparing the short peptide by the direct degradation of corn protein powder through an enzyme method and the applications of the short peptide product. The dry powder of the corn short peptide product is yellowish powder, and the molecular weight of the functional corn short peptide product is mainly distributed below 1000. The functional corn short peptide product is a short peptide mixture containing 2 to 9 amino acid residues, and average chain length is as long as 4 to 5 amino acids measured by a TNBS method. The preparation method comprises the steps of raw material pretreatment, enzyme hydrolysis, enzyme inactivation, refinement, drying, powder making, etc., and corn peptide of the present invention has the advantages of simple preparation process, good physical characters (low molecular weight, high stability, etc.) and various physiological functions (an anti-fatigue function, the function of regulating ethanol metabolism, a strong anti-oxidation function, etc.) and can be used for the production of health foods, pharmaceuticals and cosmetics as substrates.
It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
The invention discloses a vision-improving oral liquid and a preparation method thereof. The vision-improving oral liquid comprises the following materials according to mass ratio: a lutein ester emulsion, a medlar extracting solution, a chrysanthemum extracting solution, a concentrated blueberry juice and purified water at the ratio of (0.002-0.003):(0.4-0.6):(0.3-0.5):(1-2):(5-6). According to the oral liquid, the lutein ester is degraded by a human body into lutein and then plays the role, the chrysanthemum has the effects of reducing blood pressure, eliminating cancer cells, expanding the coronary artery, and inhibiting bacteria, also has better curative effects for dry eyes caused by hot liver fire and eye overuse, and has better curative effects of treating eye fatigue and blurred vision. The medlar has the effects of nourishing liver and kidney, and improving visual acuity. The blueberry can relieve the eye fatigue to make the eye continue to work, is rich in vitamin A, has the main ingredient of anthocyanin, and directly speeds up the synthesis and regeneration of retina and rhodopsin to make the eyes burst with vitality and shine. The anthocyanin in the blueberry promotes the regeneration of the rhodopsin in a retina cell, so as to prevent nearsightedness and improve vision.
Cancer is a heterogeneous disease requiring costly genetic profiling for better understanding and management. Recent advances in deep learning have enabled cost-effective predictions of genetic alterations from whole slide images (WSIs). While transformers have driven significant progress in non-medical domains, their application to WSIs lags behind due to high model complexity and limited dataset sizes. Here, we introduce SEQUOIA, a linearized transformer model that predicts cancer transcriptomic profiles from WSIs. SEQUOIA is developed using 7584 tumor samples across 16 cancer types, with its generalization capacity validated on two independent cohorts comprising 1368 tumors. Accurately predicted genes are associated with key cancer processes, including inflammatory response, cell cycles and metabolism. Further, we demonstrate the value of SEQUOIA in stratifying the risk of breast cancer recurrence and in resolving spatial gene expression at loco-regional levels. SEQUOIA hence deciphers clinically relevant information from WSIs, opening avenues for personalized cancer management.
Risk Summary

Lactation studies have not been conducted with bupivacaine. Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Bupivacaine hydrochloride injection should be administered to lactating women only if clearly indicated. Studies assessing the effects of bupivacaine hydrochloride injection in breastfed children have not been performed. Studies to assess the effect of bupivacaine hydrochloride injection on milk production or excretion have not been performed. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for bupivacaine and any potential adverse effects on the breastfed child from bupivacaine or from the underlying maternal condition.
Methods and compositions are provided for the treatment of pain and cystic fibrosis. The methods include administering to an animal a composition or a pharmaceutical formulation comprising a therapeutically effective amount of a Prostatic Acid Phosphatase ('PAP') polypeptide, or an active variant, fragment or derivative thereof, or a therapeutically effective amount of an activity enhancing PAP modulator. PAP is provided as a treatment for chronic pain including neuropathic and inflammatory pain in animals and humans. The PAP, or the active variant, fragment or derivative thereof, or the activity enhancing modulator of the PAP is administered via one or more of injection, intrathecal injection, oral administration, a surgically implanted pump, stem cells, viral gene therapy, or naked DNA gene therapy. Intrathecal injection of PAP functions as an analgesic and reduces thermal sensitivity in mice. PAP can reduce chronic mechanical and thermal inflammatory pain in mice. Allodynia and hyperalgesia due to nerve injury can be prevented by increasing PAP activity in spinal cord.
Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
Weekly or monthly dose of ABI-5366 (tablet) in Part B for Cohorts 1-4. May have a loading dose.
The plaster (1) useful as therapeutic agent for the local treatment of the skin, comprises a compound (3) such as clay powder with optionally wet active substance, and a preparation with a binder. The compound and the binder are placed together in a flexible casing (5) that is hydrophilic and adapted to traverse the active substance of the compound. The substance is contacted with a person's skin after traversing through the casing. The casing is present in a form of adjacent cells (7a, 7b, 7c) that are individually closed by welded areas oriented according to two different directions. The plaster (1) useful as therapeutic agent for the local treatment of the skin, comprises a compound (3) such as clay powder with optionally wet active substance, and a preparation with a binder. The compound and the binder are placed together in a flexible casing (5) that is hydrophilic and adapted to traverse the active substance of the compound. The substance is contacted with a person's skin after traversing through the casing. The casing is present in a form of adjacent cells (7a, 7b, 7c) that are individually closed by welded areas oriented according to two different directions. The welded areas have mechanically weakened portions to facilitate a separation between cells or groups of adjacent cells. The casing is made of a non-woven material, a cellulosic biocompatible natural material, and a water soluble material.
Regular monitoring of bacterial susceptibility to antibiotics in clinical settings is key for ascertaining the current trends as well as re-establish empirical therapy. This study aimed to determine bacterial contaminants and their antimicrobial susceptibility patterns from medical equipment, inanimate surfaces and clinical samples obtained from Thika Level V Hospital (TLVH), Thika, in Central Kenya. Three hundred and five samples were collected between the period of March 2021 to November 2021 and comprised urine, pus swabs, catheter swabs, stool, and environmental samples. Bacterial identification and antimicrobial susceptibility were performed using VITEK 2 and disc diffusion respectively. We observed that Coagulase-negative Staphylococci (28 /160, 17.5%) were the most commonly isolated species from clinical samples followed by E. coli (22 /160 13.8%) and S. aureus (22/160, 13.8%). The bed rails were the mostly contaminated surface with S. aureus accounting for 14.2% (6/42). Among the clinical samples, pus swabs yielded the highest number of pathogens was pus (92/160). Trauma patients had the highest proportion of isolates (67/160, 41.8%). High level of antimicrobial resistance to key antimicrobials, particularly among Enterobacterales was observed. Extended Spectrum Beta Lactamase (ESBL) phenotype was noted in 65.9% (29/44) of enteric isolates. While further ESBL genetic confirmatory studies are needed, this study highlights the urgent need for actions that mitigate the spread of antibiotic-resistant bacteria.
Research links the processes of fear conditioning and extinction to the treatment of anxiety and stress-related disorders. Moreover, considerable translational research examines the neural correlates of these processes. However, virtually no research in humans manipulates neural correlates of these processes, which limits basic-clinical integration. The present study aimed to use transcranial electrical stimulation (tES) to modulate processes associated with fear extinction in order to assess the potential utility of tES in enhancing exposure-based treatment. To this end, healthy participants underwent a three-day fear conditioning and extinction paradigm. Participants were randomly assigned into 3 groups, differing in terms of tES applied during the extinction learning phase (Day 2) and targeting the medial prefrontal cortex: 1) direct current (DC) stimulation, aimed at enhancing extinction learning; 2) alternate current (AC) stimulation, aimed at interfering with reconsolidation of the fear memory activated during the extinction phase; and 3) sham stimulation. The outcome measures (outlined next) involve the assessment of extinction recall during a test phase (Day 3). Successful modulation of extinction learning by tES would be reflected in enhanced extinction recall.
Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
The overall long-term goal of this project is to prevent AD, which affects almost 50% of the US population over 85 years of age, and is the most common cause of dementia. Clinical signs and symptoms of AD include cognitive impairments, especially memory and emotional disturbances. In order to accomplish this goal of prevention, a population at risk must be identified. Evidence suggests that both TBI and PTSD increase risk for cognitive decline, AD, and dementia.

TBI and PTSD are common problems resulting from military service. Thus far, there have been no prospective studies using imaging and biomarkers, which directly measure changes in the brain and AD pathology to study the effects of TBI and PTSD. This proposed study will provide novel data to test these hypotheses. The results will have major implications for identifying, subjects at increased risk for AD, a possible need for early detection of AD in military Veterans with histories of TBI and PTSD, and a possible need to employ prevention and treatment measures to avoid accelerated development of AD in US military Veterans. This study is a first step toward a larger, more comprehensive study of dementia risk factors in Veterans. The results will lead to a design and statistical powering of a prevention trial. Therefore, this project could be the first step toward the prevention of AD in Veterans, and in the general population.
Get Palliative Care educational learning module videos available online in the public domain. A Webinar: How to Manage Shortness of Breath and Improve Your Quality of Life (2019) presented by Tara Liberman, DO reviews how to live with COPD, where and when palliative care can be implemented, what alternatives to treatment may look like, and final provides a summary of the benefits of palliative care. Each learning module is approximately five to seven minutes in length. The four learning modules are accessible at https://youtu.be/__phRXS4jZs?si=TivFch6cFE6roXDZ. After completing the weekly learning module, the participant will log their viewing in REDCap via a link provided to the participant by the email provided at the time of enrollment.
Observational research has linked intake of non-nutritive sweeteners (NNS), which are consumed daily by \~50% of middle-aged/older U.S. adults, with increased risk of type 2 diabetes (T2D). This risk may be exacerbated by advancing age, which is associated with low-grade chronic inflammation and increased risk of T2D. Current T2D prevention recommendations related to NNS usage are unclear and confusing; use as an alternative to added sugar intake is suggested but long-term NNS use is discouraged despite minimal research to support this recommendation. Animal and observational human studies suggest detrimental effects of some NNS on glucose homeostasis. Longer-term human studies largely demonstrate null findings. Differences in study design and a lack of rigor in existing research contribute to inconclusive findings. In addition, NNS are often studied as a single entity yet types of NNS vary in their absorption and metabolism (e.g., the two most commonly consumed NNS, sucralose and aspartame). Whether NNS consumption impacts glucose homeostasis in middle-aged/older adults with prediabetes is unknown, and potential mechanisms by which this could occur have yet to be identified. The overall objective of this R21 proposal is to establish proof-of-concept for alterations in glucose homeostasis following intake of sucralose, but not aspartame, in middle-aged/older adults with prediabetes compared to a eucaloric diet with no NNS. We will investigate changes in inflammatory markers as potential mechanisms by which sucralose intake influences glucose homeostasis. Following a 2-week eucaloric lead-in diet, 51 middle-aged/older adults (50+ yrs) with prediabetes will be randomly assigned to 1 of 3 controlled feeding conditions for 6 weeks (17 participants per group): sucralose, aspartame, or a control group (no NNS). Standardized diets will be matched for macronutrients (50% carbohydrate, 35% fat, 15% protein) and other variables to avoid the potential confounds of weight change and dietary factors which may influence study outcomes (e.g., added sugars). All groups will receive identical diets, other than the additional NNS for the two NNS groups. 24-hr glycemic control using continuous glucose monitoring and insulin sensitivity and beta cell function via oral glucose tolerance test (OGTT), serum endotoxin, and inflammatory cytokines, including C-reactive protein, will be measured before and following the 6-week dietary treatment period. This research may have clinical practice and policy implications by informing U.S. dietary guidelines and guidelines for T2D prevention, which devote minimal attention to NNS and provide unclear guidance on NNS use due largely to a lack of rigorously-designed controlled feeding trials.